Peptide Calculator

Vial and water math for Dulaglutide, with a research record of published human trials. Math only, no suggested amounts.

Free · no account needed
1

Compound (Optional)

2

Desired Amount Per Dose

mg
units (U-100)
3

Vial Strength (Total mg of Your Vial)

mg
4

Reconstitution Solution Added

mL
5

Titration Schedule (Optional)

Results
Draw to
—units
Enter amount, vial and Reconstitution Solution
ConcentrationConc.
—mg/mL
Your dose
—mg
Doses / vial
—
U-100 Syringe · 1 mL
PeptideWhizpeptidewhiz.app · research use only
Vial ToolsReconstitution Solution amount, syringe picker, first vial walkthrough, vial timeline and COA check.
Research use only (RUO). Results are math on the values you enter only, not a recommendation or prescription for human use. Not medical advice. Always verify your own measurements. Full disclaimer

About Dulaglutide

Dulaglutide is a GLP-1 analogue joined to a fragment of an antibody (an Fc region). The large fused protein is cleared slowly, which allows once-weekly dosing in trials.

Research status

Dulaglutide is the active ingredient in the FDA-approved prescription medicine Trulicity for type 2 diabetes. It is often the active comparator in newer trials, including several of the retatrutide studies below.

How the math works for any vial (concentration, U-100 units, mg and mcg) is explained step by step on the main peptide reconstitution calculator page. Read the full What is Dulaglutide? guide for mechanism, trials and conditions researched.

What published studies used

Research record, not a recommendation or protocol

These are published human trials of Dulaglutide from the PeptideWhiz study library. The last column quotes each study’s PubMed abstract word for word, so it shows what that study reported giving its participants under medical supervision. It is not advice, and the calculator never fills these numbers in on its own: you can copy one only by tapping its button and confirming.

StudyYearJournalAs reported in the abstractPubMed
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.2026Diabetes, obesity & metabolism“In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.”PMID 42608321
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.2025The lancet. Diabetes & endocrinology“Eligible participants were randomly assigned in a 2:2:2:1:1:1:1:2 ratio to once-weekly subcutaneous placebo, dulaglutide 1·5 mg, or retatrutide 0·5 mg, 4 mg (2 mg initial dose), 4 mg (4 mg initial dose), 8 mg (2 mg initial dose), 8 mg (4 mg initial dose), or 12 mg.”PMID 40609566
Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.2021Diabetes, obesity & metabolism“Healthy subjects (aged 18-75 years; body mass index ≥ 25 kg/m2 ; n = 104) were randomized 1:1, using a pregenerated list, to semaglutide 0.25 mg as the first injection and dulaglutide 0.75 mg as the second injection or vice versa; each was administered using their proprietary pen-injectors, according to instructions for use.”PMID 33591618
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.2020The lancet. Diabetes & endocrinology“Patients aged 20 years and older with uncontrolled type 2 diabetes were randomly assigned (2:2:2:1) to receive once-daily oral semaglutide 3 mg, 7 mg, or 14 mg, or once-weekly subcutaneous dulaglutide 0·75 mg for 52 weeks, as an add-on to their background medication.”PMID 32333876
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.2020Diabetes care“Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.”PMID 32291277

Disclaimer: this table is an educational research record. It does not recommend, suggest or endorse any amount, schedule or use, and it is not medical advice. Decisions about any medicine belong with a licensed clinician.

Dulaglutide calculator FAQ

What is Dulaglutide?

Dulaglutide is a GLP-1 receptor agonist. Dulaglutide is a GLP-1 analogue joined to a fragment of an antibody (an Fc region).

Is Dulaglutide approved?

Dulaglutide is the active ingredient in the FDA-approved prescription medicine Trulicity for type 2 diabetes. It is often the active comparator in newer trials, including several of the retatrutide studies below.

Does this page suggest a Dulaglutide dose?

No. The calculator dose field starts empty and PeptideWhiz never suggests, recommends or calculates an amount for anyone. The study table is a research record of what published trials reported, not a recommendation or protocol.

Where do the study numbers on this page come from?

Each row quotes the abstract of a published human trial (5 trials, 2020 to 2026) word for word, as indexed in PubMed, with a link to the PubMed record. Nothing is rounded, combined or converted.

How does the calculator work with a Dulaglutide vial?

Pick Dulaglutide in step 1 if you want it on your result card, then enter the vial amount printed on your own label and the water volume actually added. The tool divides one by the other for concentration and shows the matching U-100 syringe units for an amount you type. Pens and pre-filled syringes are already in liquid form and are not reconstituted.

Sources

Study rows: PubMed records linked in the table (abstracts checked against PubMed on October 31, 2026). Unit math: see the sources on the main calculator.

Reviewed by the PeptideWhiz team on October 31, 2026. For research and education only.